Shares of TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report) traded down 2.7% on Friday . The company traded as low as $0.41 and last traded at $0.42. 1,391,477 shares traded hands during trading, an increase of 110% from the average session volume of 662,359 shares. The stock had previously closed at $0.43.
TNF Pharmaceuticals Stock Performance
The firm has a 50-day moving average of $0.93.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
Featured Articles
- Five stocks we like better than TNF Pharmaceuticals
- The Role Economic Reports Play in a Successful Investment Strategy
- Realty Income: An Anchor in Volatile Markets
- Overbought Stocks Explained: Should You Trade Them?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- CD Calculator: Certificate of Deposit Calculator
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
